

JAZZ PHARMACEUTICALS PLC
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION - 2019 BY QUARTER

To supplement Jazz Pharmaceuticals plc's financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures. The tables that follow present certain financial information on a GAAP reported and non-GAAP adjusted basis for Jazz Pharmaceuticals plc and its consolidated subsidiaries for the periods specified, along with reconciliations of the non-GAAP financial measures presented to the most directly comparable GAAP reported measures. The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts. In particular, the company believes that each of these non-GAAP financial measures, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance, and to identify operating trends in the company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company's financial performance. Jazz Pharmaceuticals' management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for Jazz Pharmaceuticals' management, the company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the company uses in assessing its own operating performance and making operating decisions.

The non-GAAP financial measures included in the accompanying tables are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's condensed consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. For example, commencing with the presentation of the company's financial guidance for 2020, the company will no longer exclude upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. Accordingly, while certain of such payments are excluded from its non-GAAP financial measures for the year ended December 31, 2019, as detailed in the reconciliation tables that follow, such presentation is made solely for comparability and transition purposes and will not be continued going forward. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by the company in the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

JAZZ PHARMACEUTICALS PLC
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION - 2019 BY QUARTER

In thousands, except per share amounts (Unaudited)	1Q19	2Q19	3Q19	4Q19	2019
GAAP reported net income	\$ 85,201	\$ 261,898	\$ 102,276	\$ 73,992	\$ 523,367
Intangible asset amortization	56,885	61,576	62,863	173,490	354,814
Share-based compensation expense	27,552	28,289	28,785	25,937	110,563
Upfront & milestone payments ^(a)	56,000	-	48,275	-	104,275
Non-cash interest expense	11,133	11,451	11,831	11,981	46,396
Income tax effect of above adjustments	(23,598)	(18,403)	(18,752)	(32,157)	(92,910)
Income tax benefit related to intra-entity intellectual property asset transfer	-	(112,274)	-	-	(112,274)
Non-GAAP adjusted net income	\$ 213,173	\$ 232,537	\$ 235,278	\$ 253,243	\$ 934,231
GAAP reported net income per diluted share	1.47	4.56	1.78	1.29	9.09
Non-GAAP adjusted net income per diluted share	3.67	4.05	4.10	4.42	16.23
Weighted-average ordinary shares used in diluted per share calculation	58,081	57,427	57,438	57,262	57,550

Explanation of Adjustments and Certain Line Items (in thousands):

(a) The amount includes a \$56,000 upfront payment to Codiak BioSciences, Inc. under a collaboration agreement in the three months ended March 31, 2019 and \$48,275 attributed to acquired in-process research and development expense related to the acquisition of Cavion, Inc. in the three months ended September 30, 2019.

JAZZ PHARMACEUTICALS PLC
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS - 2019 BY QUARTER

Period	In thousands (Unaudited)	Cost of product sales	Selling, general and administrative	Research and development	Intangible asset amortization	Acquired IPR&D	Interest expense, net	Income tax provision (benefit)
2019	GAAP Reported	\$ 127,930	\$ 736,942	\$ 299,726	\$ 354,814	\$ 109,975	\$ 72,261	\$ (73,154)
	Non-GAAP Adjustments							
	Intangible asset amortization	-	-	-	(354,814)	-	-	-
	Share-based compensation expense	(6,637)	(78,697)	(25,229)	-	-	-	-
	Upfront & milestone payments	-	-	-	-	(104,275)	-	-
	Non-cash interest expense	-	-	-	-	-	(46,396)	-
	Income tax effect of above adjustments	-	-	-	-	-	-	92,910
	Income tax benefit related to intra-entity intellectual property asset transfer	-	-	-	-	-	-	112,274
	Total of Non-GAAP adjustments	(6,637)	(78,697)	(25,229)	(354,814)	(104,275)	(46,396)	205,184
	Non-GAAP Adjusted	\$ 121,293	\$ 658,245	\$ 274,497	\$ -	\$ 5,700	\$ 25,865	\$ 132,030
4Q19	GAAP Reported	\$ 35,348	\$ 214,275	\$ 97,382	\$ 173,490	\$ -	\$ 18,244	\$ (34,523)
	Non-GAAP Adjustments							
	Intangible asset amortization	-	-	-	(173,490)	-	-	-
	Share-based compensation expense	(1,285)	(17,340)	(7,312)	-	-	-	-
	Non-cash interest expense	-	-	-	-	-	(11,981)	-
	Income tax effect of above adjustments	-	-	-	-	-	-	32,157
	Total of Non-GAAP adjustments	(1,285)	(17,340)	(7,312)	(173,490)	-	(11,981)	32,157
	Non-GAAP Adjusted	\$ 34,063	\$ 196,935	\$ 90,070	\$ -	\$ -	\$ 6,263	\$ (2,366)
3Q19	GAAP Reported	\$ 31,400	\$ 178,706	\$ 79,855	\$ 62,863	\$ 51,775	\$ 17,861	\$ 10,903
	Non-GAAP Adjustments							
	Intangible asset amortization	-	-	-	(62,863)	-	-	-
	Share-based compensation expense	(1,985)	(20,302)	(6,498)	-	-	-	-
	Upfront & milestone payments	-	-	-	-	(48,275)	-	-
	Non-cash interest expense	-	-	-	-	-	(11,831)	-
	Income tax effect of above adjustments	-	-	-	-	-	-	18,752
	Total of Non-GAAP adjustments	(1,985)	(20,302)	(6,498)	(62,863)	(48,275)	(11,831)	18,752
	Non-GAAP Adjusted	\$ 29,415	\$ 158,404	\$ 73,357	\$ -	\$ 3,500	\$ 6,030	\$ 29,655
2Q19	GAAP Reported	\$ 27,676	\$ 176,014	\$ 62,384	\$ 61,576	\$ 2,200	\$ 18,234	\$ (78,650)
	Non-GAAP Adjustments							
	Intangible asset amortization	-	-	-	(61,576)	-	-	-
	Share-based compensation expense	(1,708)	(20,685)	(5,896)	-	-	-	-
	Non-cash interest expense	-	-	-	-	-	(11,451)	-
	Income tax effect of above adjustments	-	-	-	-	-	-	18,403
	Income tax benefit related to intra-entity intellectual property asset transfer	-	-	-	-	-	-	112,274
	Total of Non-GAAP adjustments	(1,708)	(20,685)	(5,896)	(61,576)	-	(11,451)	130,677
	Non-GAAP Adjusted	\$ 25,968	\$ 155,329	\$ 56,488	\$ -	\$ 2,200	\$ 6,783	\$ 52,027
1Q19	GAAP Reported	\$ 33,506	\$ 167,947	\$ 60,105	\$ 56,885	\$ 56,000	\$ 17,922	\$ 29,116
	Non-GAAP Adjustments							
	Intangible asset amortization	-	-	-	(56,885)	-	-	-
	Share-based compensation expense	(1,659)	(20,370)	(5,523)	-	-	-	-
	Upfront & milestone payments	-	-	-	-	(56,000)	-	-
	Non-cash interest expense	-	-	-	-	-	(11,133)	-
	Income tax effect of above adjustments	-	-	-	-	-	-	23,598
	Total of Non-GAAP adjustments	(1,659)	(20,370)	(5,523)	(56,885)	(56,000)	(11,133)	23,598
	Non-GAAP Adjusted	\$ 31,847	\$ 147,577	\$ 54,582	\$ -	\$ -	\$ 6,789	\$ 52,714